hPMSCs inhibit the expression of PD-1 in CD4+IL-10+ T cells and mitigate liver damage in a GVHD mouse model by regulating the crosstalk between Nrf2 and NF-κB signaling pathway

Table 1 Patient information

GVHD patient no.	1	2	3	4	5	6	7
Age (y)	30–39	20–29	20–29	50–59	40–49	50–59	0–9
Sex	1	2	1	1	1	1	1
Diagnosis	ALL	AML	AA	AML	ALL	ALL	AA
Stem cell source	HSC and PBSC	HSC and PBSC	HSC and PBSC	HSC and PBSC	HSC and PBSC	HSC and PBSC	HSC and PBSC
GVHD prophylaxis	Tacrolimus	Tacrolimus and cyclosporine A	Cyclosporine A	Cyclosporine A and mycophenolic acid and methotrexate	Cyclosporine A and mycophenolic acid and methotrexate	Cyclosporine A and mycophenolic acid	Cyclosporine A
Match	MFD	MFD	MFD	MFD	MFD	MFD	MFD
Concomitant drug therapy	Tacrolimus	Tacrolimus	Cyclosporine A	Methylprednisolone and cyclosporine A	Cyclosporine A	Cyclosporine A	Cyclosporine A

ALL acute lymphoblastic leukemia, AML acute myelocytic leukemia, AA aplastic anemia, HSC hematopoietic stem cell, PBMC peripheral blood stem cell, MFD matched familiar donor

ISSN: 1757-6512